ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Cephalon Makes an Offer For Arana

by Ann M. Thayer
March 9, 2009 | APPEARED IN VOLUME 87, ISSUE 10

Cephalon has made a $207 million offer to acquire the 80% of Australia’s Arana Therapeutics that it does not already own. Arana develops antibody-based drugs to treat inflammatory diseases and cancer. Its lead candidate, a tumor necrosis factor alpha blocker, is in Phase II trials for both psoriasis and rheumatoid arthritis. The company also receives royalties from Abbott Laboratories and Johnson & Johnson for technology licenses. Arana’s independent directors are recommending that shareholders accept the deal in the absence of a better proposal.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment